| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
MANE
Veradermics, Incorporated
|
Jun 16, 2026 | BUY |
Strong Buy
+31.9% avg upside
6 analysts
|
$138.00
47.09% Upside
|
· |
|
NRIX
Nurix Therapeutics
|
Jun 15, 2026 | BUY |
Strong Buy
+75.6% avg upside
26 analysts
|
$45.00
156.39% Upside
|
· |
|
KLRA
Kailera Therapeutics, Inc.
|
May 28, 2026 | BUY |
Strong Buy
+96.0% avg upside
5 analysts
|
$48.00
141.26% Upside
|
· |
|
AVLN
Avalyn Pharma Inc
|
May 26, 2026 | BUY |
Strong Buy
+65.3% avg upside
3 analysts
|
$52.00
65.28% Upside
|
· |
|
SABS
SAB Biotherapeutics
|
May 20, 2026 | BUY |
Strong Buy
+161.3% avg upside
13 analysts
|
$11.00
174.93% Upside
|
· |
|
UTHR
United Therapeutics
|
May 19, 2026 | BUY |
Buy
-18.7% avg upside
26 analysts
|
$733.00
36.59% Upside
|
-2.7% |
|
FATE
Fate Therapeutics
|
May 19, 2026 | BUY |
Buy
+475.7% avg upside
31 analysts
|
$4.00
91.38% Upside
|
+4.8% |
|
KNSA
Kiniksa Pharmaceuticals
|
Apr 28, 2026 | BUY |
Strong Buy
-0.2% avg upside
11 analysts
|
$71.00
28.76% Upside
|
-2.8% |
|
ALLO
Allogene Therapeutics
|
Apr 15, 2026 | BUY |
Strong Buy
+662.1% avg upside
28 analysts
|
$10.00
399.91% Upside
|
-12.4% |
|
REPL
Replimune Group
|
Apr 12, 2026 | HOLD |
Hold
+72.3% avg upside
13 analysts
|
$2.00
80.31% Downside
|
+499.4% |
|
BIOA
BioAge Labs, Inc.
|
Mar 26, 2026 | BUY |
Strong Buy
+138.3% avg upside
9 analysts
|
$62.00
198.49% Upside
|
+8.7% |
|
WVE
Wave Life Sciences
|
Mar 26, 2026 | BUY |
Strong Buy
+260.5% avg upside
28 analysts
|
$18.00
192.30% Upside
|
-0.7% |
|
CABA
Cabaletta Bio
|
Mar 23, 2026 | BUY |
Strong Buy
+390.0% avg upside
16 analysts
|
$14.00
393.02% Upside
|
+17.4% |
|
CTMX
CytomX Therapeutics
|
Mar 18, 2026 | BUY |
Strong Buy
+269.6% avg upside
21 analysts
|
$16.00
442.27% Upside
|
-31.6% |
|
ORKA
Oruka Therapeutics
|
Mar 11, 2026 | BUY |
Strong Buy
+61.8% avg upside
16 analysts
|
$45.00
37.85% Downside
|
+106.0% |
|
GPCR
Structure Therapeutics, Inc. Sponsored ADR
|
Feb 27, 2026 | BUY |
Strong Buy
+132.5% avg upside
17 analysts
|
$125.00
180.90% Upside
|
-41.9% |
|
KRYS
Krystal Biotech
|
Feb 17, 2026 | BUY |
Strong Buy
-28.3% avg upside
19 analysts
|
$371.00
6.55% Upside
|
+18.7% |
|
VKTX
Viking Therapeutics
|
Feb 12, 2026 | BUY |
Strong Buy
+141.1% avg upside
30 analysts
|
$101.00
232.38% Upside
|
-2.8% |
|
CRVS
Corvus Pharmaceuticals
|
Jan 22, 2026 | BUY |
Strong Buy
+114.5% avg upside
14 analysts
|
$42.00
252.74% Upside
|
-53.0% |
|
IRON
Disc Medicine
|
Dec 19, 2025 | BUY |
Strong Buy
+20.2% avg upside
21 analysts
|
$154.00
117.63% Upside
|
-12.4% |
|
NKTR
Nektar Therapeutics
|
Dec 17, 2025 | BUY |
Buy
+16.5% avg upside
25 analysts
|
$121.00
98.43% Upside
|
+34.1% |
|
KURA
Kura Oncology
|
Dec 10, 2025 | BUY |
Strong Buy
+161.3% avg upside
26 analysts
|
$28.00
182.01% Upside
|
-10.9% |
|
GYRE
Gyre Therapeutics
|
Oct 10, 2025 | BUY |
Strong Buy
+212.0% avg upside
15 analysts
|
$16.00
156.04% Upside
|
-19.2% |
|
STRO
Sutro Biopharma
|
Sep 09, 2025 | BUY |
Strong Buy
+31.6% avg upside
20 analysts
|
$40.00
34.92% Upside
|
+196.9% |
|
BMEA
Biomea Fusion
|
Aug 28, 2025 | BUY |
Strong Buy
+1037.0% avg upside
15 analysts
|
$5.00
323.72% Upside
|
-24.0% |
|
ATYR
aTyr Pharma
|
Aug 22, 2025 | BUY |
Buy
+2023.9% avg upside
17 analysts
|
$17.00
3673.52% Upside
|
-90.3% |
|
EQ
Equillium
|
Aug 20, 2025 | BUY |
Strong Buy
+181.9% avg upside
14 analysts
|
$4.00
31.12% Upside
|
+143.0% |
|
MBX
MBX Biosciences, Inc.
|
Aug 15, 2025 | BUY |
Strong Buy
+53.4% avg upside
14 analysts
|
$36.00
16.35% Downside
|
+172.4% |
|
INO
Inovio Pharmaceuticals
|
Aug 13, 2025 | BUY |
Buy
+808.3% avg upside
19 analysts
|
$1.80
61.53% Upside
|
-35.3% |
|
ALT
Altimmune
|
Jun 26, 2025 | BUY |
Strong Buy
+935.8% avg upside
19 analysts
|
$28.00
937.04% Upside
|
-19.7% |
|
VXRT
Vaxart
|
Jun 11, 2025 | BUY |
Strong Buy
+1315.6% avg upside
8 analysts
|
$8.00
1351.91% Upside
|
+52.0% |
|
TGTX
TG Therapeutics
|
May 05, 2025 | BUY |
Strong Buy
-34.4% avg upside
19 analysts
|
$46.00
13.50% Downside
|
-4.2% |
|
ACRS
Aclaris Therapeutics
|
Apr 24, 2025 | BUY |
Strong Buy
+122.5% avg upside
15 analysts
|
$7.00
55.48% Upside
|
+238.6% |
|
PTGX
Protagonist Therapeutics
|
Apr 10, 2025 | BUY |
Strong Buy
-22.1% avg upside
19 analysts
|
$68.00
39.85% Downside
|
+141.7% |
|
AKBA
Akebia Therapeutics
|
Apr 01, 2025 | BUY |
Strong Buy
+822.0% avg upside
16 analysts
|
$6.00
460.83% Upside
|
-26.2% |
|
PCVX
Vaxcyte
|
Mar 31, 2025 | BUY |
Strong Buy
+96.1% avg upside
15 analysts
|
$146.00
183.89% Upside
|
+53.9% |
|
ACRV
Acrivon Therapeutics, Inc.
|
Mar 26, 2025 | BUY |
Strong Buy
+817.2% avg upside
13 analysts
|
$18.00
1046.57% Upside
|
-45.6% |
|
SANA
Sana Biotechnology
|
Mar 14, 2025 | BUY |
Strong Buy
+214.8% avg upside
14 analysts
|
$7.00
122.21% Upside
|
+14.7% |
|
IOBTQ
IO Biotech
|
Jan 27, 2025 | BUY |
Buy
+78483.3% avg upside
6 analysts
|
$8.00
133233.36% Upside
|
· |
|
ZBIO
Zenas BioPharma, Inc.
|
Jan 10, 2025 | BUY |
Strong Buy
+102.2% avg upside
11 analysts
|
$35.00
76.86% Upside
|
+98.0% |
|
NUVL
Nuvalent
|
Dec 20, 2024 | BUY |
Buy
-0.3% avg upside
21 analysts
|
$137.00
11.01% Upside
|
+23.2% |
|
NVAX
Novavax
|
Oct 16, 2024 | BUY |
Buy
+154.1% avg upside
20 analysts
|
$25.00
173.89% Upside
|
-16.4% |
|
WHWK
Whitehawk Therapeutics
|
Aug 21, 2024 | HOLD |
Buy
+201.4% avg upside
12 analysts
|
$1.50
65.99% Downside
|
+6.5% |
|
CBIO
Crescent Biopharma
|
Mar 27, 2024 | BUY |
Strong Buy
+26.9% avg upside
17 analysts
|
$3.00
83.08% Downside
|
· |
|
CLDX
Celldex
|
Nov 05, 2023 | BUY |
Strong Buy
+20.6% avg upside
28 analysts
|
$68.00
109.68% Upside
|
-13.4% |
|
VAXX
Vaxxinity Inc
|
Jan 12, 2023 | BUY |
Buy
+73233.3% avg upside
4 analysts
|
$15.00
99899.96% Upside
|
-69.1% |
|
PRLD
Prelude Therapeutics
|
Jul 29, 2022 | BUY |
Buy
+151.3% avg upside
7 analysts
|
$9.00
108.27% Upside
|
-20.4% |
|
PVLA
Palvella Therapeutics
|
May 18, 2021 | BUY |
Strong Buy
+45.3% avg upside
27 analysts
|
$6.00
94.64% Downside
|
· |
|
TVRD
Tvardi Therapeutics
|
Apr 29, 2021 | BUY |
Buy
+585.4% avg upside
23 analysts
|
$23.00
774.56% Upside
|
-38.0% |
|
FNCHQ
Finch Therapeutics Group
|
Apr 13, 2021 | BUY |
Strong Buy
+183.5% avg upside
3 analysts
|
$29.00
233.26% Upside
|
· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.